drugset / Trial / NCT00005598
Azacitidine Plus Amifostine in Treating Patients With Myelodysplastic Syndrome
Phase 2
Completed
University of Michigan Rogel Cancer Center
National Cancer Institute (NCI) · collab
Treatment
Summary
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Amifostine may improve blood counts in patients with myelodysplastic syndrome. Combining azacitidine with amifostine may kill more cancer cells. PURPOSE: Phase II trial to study the effectiveness of azacitidine plus amifostine in treating patients who have myelodysplastic syndrome.
Timeline
- Start
- 2000-10
- Primary completion
- 2001-12
- Completion
- 2002-03
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Azacitidine | Other / unclassified | — | Subcutaneous |
| Subject | amifostine | Unknown | — | Intravenous |